Dragonfly Therapeutics (United States)

Phase 1/2 Study of DF1001, a novel tri-specific, NK cell engager therapy targeting HER2, in patients with advanced solid tumors: Phase 1 DF1001 monotherapy dose-escalation results.

Howard Safran, Philippe A. Cassier, Cécile Vicier et al. · Journal of Clinical Oncology · 2023 · 30 citations

Pharmacy, Oncology, Pharmacokinetics +17

An optimized IL-12-Fc expands its therapeutic window, achieving strong activity against mouse tumors at tolerable drug doses

Eva Gutiérrez, Mitchell Bigelow, Colin LaCroix et al. · Med · 2023 · 19 citations

Life Sciences, Immunology, Pharmacology +17

Structures of activin ligand traps using natural sets of type I and type II TGFβ receptors

Erich J. Goebel, Chandramohan Kattamuri, Gregory R. Gipson et al. · iScience · 2021 · 17 citations · Full text

Life Sciences, Medicinal Chemistry, Molecular Biology +15

Direct capture of neutralized RBD enables rapid point-of-care assessment of SARS-CoV-2 neutralizing antibody titer

Guinevere G. Connelly, Orville O. Kirkland, Seven Bohannon et al. · Cell Reports Methods · 2022 · 16 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +16

Online monitoring and control of upstream cell culture process using 1D and 2D‐LC with SegFlow interface

Letha Chemmalil, Dhanuka P. Wasalathanthri, Xin Zhang et al. · Biotechnology and Bioengineering · 2021 · 12 citations

Life Sciences, Bioengineering, Biotechnology +17